Ethicon expands hemostasis portfolio

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
Ethicon, a Johnson & Johnson company, has introduced its Ethicon Omnex Surgical Sealant, its synthetic sealant designed to achieve adjunctive hemostasis in vascular reconstructions by mechanically sealing areas of leakage.

The FDA recently granted the premarket approval application for Ethicon Omnex Surgical Sealant.

Ethicon Omnex is contraindicated in patients with known hypersensitivity to cyanoacrylate or formaldehyde. The device is not for intravascular use. Ethicon Omnex Surgical Sealant is intended for use as an adjunctive sealant and is not to be used in place of sutures, staples or mechanical closure, according to the Somerville, N.J.-based company.